The above evidence suggests that while targeting FAP systemically in mice can have severe adverse effects preclinical studies show that local inhibition of FAP in the TME of tumour bearing mice can be a potent therapeutic tool to allow redistribution of CD8 T cells into the tumour. Here, CD8A is linked to neoplasm.